Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A in AIDS-Related B-Cell Lymphoma/Lympholeukemia
NCT05340829Phase 1Unknown
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of thiscart19a in B cell lymphoma and B-cell leukemia (BCL) (3 arms). Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment-Emergent Adverse Events at 28 days. Status: unknown.
02
Drugs
thiscart19a
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT05340829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340829.